baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Atos Se ATOS ORD SHS/ FR0000051732 /

5/24/2024 5:29:17 PM	Chg. -0.045	Volume	Bid5:40:09 PM	Ask5:40:09 PM	Market Capitalization	Dividend Y.	P/E Ratio
2.066EUR	-2.13%	3,494 Turnover: 5,337.918	-Bid Size: -	-Ask Size: -	229.01 mill.EUR	-	-

GlobeNewswire 5/16 Nametag Enlisted by Newfold Digital in the Fight Against Fraud and Cybersecurity Threats

GlobeNewswire 5/15 Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Tria...

GlobeNewswire 5/15 Calian Reports Record Results for the Second Quarter

GlobeNewswire 5/13 Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 5/13 NVIDIA Grace Hopper Ignites New Era of AI Supercomputing

GlobeNewswire 5/7 Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

GlobeNewswire 4/29 Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...

GlobeNewswire 4/15 Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endo...

GlobeNewswire 4/11 Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

GlobeNewswire 4/9 Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100%...

GlobeNewswire 4/1 Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

GlobeNewswire 3/27 Calian Announces the Appointment of New President of Advanced Technologies

GlobeNewswire 3/25 Nametag Launches Self-Service Account Recovery Solution That Stops AI-Generated Deepfake Attacks

GlobeNewswire 3/19 Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Acce...

GlobeNewswire 3/18 Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

GlobeNewswire 3/12 Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Dir...

GlobeNewswire 3/6 Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Can...

GlobeNewswire 2/22 Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

GlobeNewswire 1/16 New report reveals that 94% of global organizations have experienced email security incidents last y...

GlobeNewswire 1/9 Atossa Therapeutics Issues Letter to Shareholders

TeleTrader 1/3 Europe opens mixed with data, business in focus

TeleTrader 1/3 Airbus to purchase Atos' cyber security unit for $1.9B

GlobeNewswire 12/13/2023 Sodexo announces the composition of Pluxee’s future Board of Directors

GlobeNewswire 12/4/2023 Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

GlobeNewswire 11/20/2023 Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

Atos Se ATOS ORD SHS/ FR0000051732 /

If you wish to receive reply to your feedback, please provide your email address.